Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROGRAF vs ABLYSINOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Calcineurin inhibitor; binds to FKBP-12, inhibits calcineurin, preventing dephosphorylation and nuclear translocation of NF-AT, thereby inhibiting T-cell activation and cytokine gene transcription.
Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular contents and cell death. The liposomal formulation enhances delivery to fungal cells while reducing host toxicity.
Prophylaxis of organ rejection in kidney, liver, and heart transplant recipients,Treatment of refractory acute cellular rejection after organ transplantation,Off-label: Severe atopic dermatitis, nephrotic syndrome, ulcerative colitis
Empiric therapy for presumed fungal infection in febrile neutropenic patients,Treatment of systemic fungal infections (e.g., aspergillosis, candidiasis, cryptococcosis),Treatment of visceral leishmaniasis
Initial oral dose: 0.1-0.15 mg/kg/day divided into 2 doses (every 12 hours). IV dose: 0.03-0.05 mg/kg/day as continuous infusion. Adjunct with corticosteroids.
Adults: 5 mg orally once daily, increased to 10 mg once daily after 2 weeks if tolerated, maximum 10 mg daily.
Terminal elimination half-life is approximately 8.7 hours (range 4-41 hours) in healthy volunteers; in liver transplant patients, half-life is approximately 11.7 hours (range 3.9-56 hours); prolonged in patients with hepatic impairment.
Terminal elimination half-life is 4–6 hours in patients with normal renal function; prolonged to 12–24 hours in severe renal impairment (Cr Cl <30 m L/min).
Primarily hepatic via CYP3A4 and CYP3A5; intestinal metabolism contributes. P-glycoprotein substrate.
Ivermectin is metabolized primarily by CYP3A4 to hydroxylated and demethylated metabolites. Phase II glucuronidation may occur. No active metabolites are identified.
Primarily fecal (approximately 92%) with biliary excretion as the major route; renal excretion accounts for about 2.4% of the dose as unchanged drug and metabolites.
Renal excretion of unchanged drug accounts for approximately 60% of elimination; biliary/fecal excretion accounts for 30%; the remaining 10% is metabolized.
99% bound primarily to albumin and alpha-1-acid glycoprotein; also binds to erythrocytes and lipoproteins.
Approximately 85% bound to serum albumin and alpha-1-acid glycoprotein.
Volume of distribution is approximately 0.99 L/kg (range 0.6-1.9 L/kg) in healthy subjects; higher values indicate extensive tissue distribution and binding to erythrocytes.
Volume of distribution is 0.5 L/kg, indicating distribution primarily into extracellular fluid.
Oral bioavailability is approximately 17-25% (range 4-89%) in transplant patients, with high inter- and intra-subject variability; absorption is influenced by food.
Oral bioavailability is 40–50% due to first-pass metabolism; intramuscular bioavailability is 80%.
No specific GFR-based dose adjustment required, but monitor renal function closely due to nephrotoxicity. For severe renal impairment (Cr Cl <30 m L/min), reduce dose by 25-50% and monitor levels.
GFR ≥30 m L/min: no adjustment; GFR <30 m L/min: not recommended.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 25%. Child-Pugh C: reduce dose by 50% and titrate based on trough levels.
Child-Pugh A: no adjustment; Child-Pugh B or C: contraindicated.
Oral: 0.1-0.3 mg/kg/day divided every 12 hours. IV: 0.03-0.05 mg/kg/day continuous infusion. Monitor trough concentrations.
Not approved for use in pediatric patients.
Start at lower end of dosing range due to potential age-related decline in renal function. Monitor renal function and tacrolimus levels closely.
No specific dose adjustment; monitor for increased sensitivity and renal function.
Increased risk of lymphomas and other malignancies, particularly skin cancer; increased susceptibility to infections. Only should be prescribed by physicians experienced in immunosuppressive therapy.
This drug should be used primarily for treatment of progressive, potentially life-threatening fungal infections; it is not intended for non-invasive forms of disease (e.g., oral thrush, vaginal candidiasis).
Nephrotoxicity, neurotoxicity (tremor, headache, seizures), hypertension, hyperkalemia, hyperglycemia, thrombotic microangiopathy, risk of BK virus infection, increased risk of EBV-associated post-transplant lymphoproliferative disorder.
Monitor renal function closely; may cause dose-dependent nephrotoxicity. Premedicate for infusion reactions (fever, chills, rigors). Monitor electrolytes (hypokalemia, hypomagnesemia). Risk of cardiotoxicity with rapid infusion. Use caution in patients with renal impairment; dose adjustment required.
Hypersensitivity to tacrolimus or any component of the formulation, concomitant use with cyclosporine, and patients with or at risk for congenital long QT syndrome.
Hypersensitivity to amphotericin B or any component of the formulation, unless the benefit outweighs the risk.
Grapefruit and grapefruit juice increase tacrolimus levels, avoid. High-fat meals may decrease absorption; take consistently with or without food. Avoid potassium-rich foods if hyperkalemia risk.
Avoid grapefruit and grapefruit juice as they may increase fingolimod concentrations. No specific dietary restrictions, but maintain adequate hydration.
Pregnancy Category C. Risk in first trimester: increased risk of congenital malformations (animal studies); human data limited. Second and third trimester: potential for fetal growth restriction, prematurity, and neonatal toxicity (hyperkalemia, renal dysfunction). Use only if benefit outweighs risk.
Category D. First trimester: increased risk of cardiac malformations (Ebstein anomaly) and neural tube defects. Second/third trimesters: fetal toxicity including oligohydramnios, premature closure of ductus arteriosus, and neonatal renal impairment.
Excreted in breast milk; M/P ratio unknown. Weigh benefits of breastfeeding against potential risk of infant immunosuppression and renal toxicity. Consider avoiding or using alternative.
Contraindicated. Excreted in human milk; M/P ratio not determined. Potential for serious adverse reactions in breastfed infants.
Increased clearance and decreased bioavailability during pregnancy may necessitate higher doses; monitor trough concentrations frequently (every 1-2 weeks) and adjust to maintain therapeutic levels (typically 5-15 ng/m L for liver transplantation, adjust per indication). Increased dose requirements often seen in second and third trimesters.
Increased renal clearance in pregnancy may require dose increments of 30-50% to maintain therapeutic levels; monitor serum lithium concentrations and adjust dose to therapeutic range (0.6-1.2 m Eq/L).
Monitor trough levels 12 hours post-dose; target 5-20 ng/m L depending on organ. Avoid with live vaccines. Adjust dose for hepatic impairment. Cautious co-administration with nephrotoxic drugs. Grapefruit juice increases tacrolimus levels.
ABLYSINOL (fingolimod) is a sphingosine-1-phosphate receptor modulator used for relapsing forms of multiple sclerosis. First-dose monitoring for bradycardia (6 hours) is mandatory; consider pre-treatment ECG. Avoid live vaccines during and for 2 months after therapy. Monitor for macular edema (ophthalmologic exam at baseline and 3-4 months). Lymphopenia is expected; check CBC before initiation and periodically. Drug interactions: QTc-prolonging agents, immunosuppressants, beta-blockers, calcium channel blockers. Do not use in patients with recent MI, unstable angina, stroke, TIA, or certain arrhythmias.
Take at the same time every day, 12 hours apart.,Do not eat grapefruit or drink grapefruit juice.,Report signs of infection, tremors, or changes in urine output.,Avoid live vaccines and limit sun exposure.,Do not stop abruptly; taper under medical supervision.
Stay hydrated and avoid grapefruit juice; it may increase drug levels.,Report any vision changes, slow heartbeat, or dizziness immediately.,Avoid pregnancy; use effective contraception during and for 2 months after stopping.,Do not receive live vaccinations during treatment.,Take exactly as prescribed; do not skip doses or stop suddenly.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROGRAF vs ABLYSINOL, answered by our medical review team.
PROGRAF is a Calcineurin Inhibitor that works by Calcineurin inhibitor; binds to FKBP-12, inhibits calcineurin, preventing dephosphorylation and nuclear translocation of NF-AT, thereby inhibiting T-cell activation and cytokine gene transcription.. ABLYSINOL is a Calcineurin inhibitor that works by Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular contents and cell death. The liposomal formulation enhances delivery to fungal cells while reducing host toxicity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROGRAF and ABLYSINOL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROGRAF is: Initial oral dose: 0.1-0.15 mg/kg/day divided into 2 doses (every 12 hours). IV dose: 0.03-0.05 mg/kg/day as continuous infusion. Adjunct with corticosteroids.. The standard adult dose of ABLYSINOL is: Adults: 5 mg orally once daily, increased to 10 mg once daily after 2 weeks if tolerated, maximum 10 mg daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROGRAF and ABLYSINOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROGRAF is classified as Category C. Pregnancy Category C. Risk in first trimester: increased risk of congenital malformations (animal studies); human data limited. Second and third trimester: potential for fetal grow. ABLYSINOL is classified as Category C. Category D. First trimester: increased risk of cardiac malformations (Ebstein anomaly) and neural tube defects. Second/third trimesters: fetal toxicity including oligohydramnios, p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.